|
|||||
|
|
Apatinib for the treatment of gastric cancer |
|
| Authors: | Giandomenico Roviello Andrea Ravelli Anna Ida Fiaschi Maria Rosa Cappelletti Angela Gobbi Chiara Senti |
| Affiliation: | 1. Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy;2. Unit of Molecular Therapy and Pharmacogenomic, ASST Cremona, Cremona, Italy;3. Section of Experimental Oncology, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy;4. Pharmacology Unit, University of Siena, Siena, Italy;5. Unit of Molecular Therapy and Pharmacogenomic, ASST Cremona, Cremona, Italy |
| Abstract: | Introduction: Apatinib, a small-molecule inhibitor of vascular endothelial growth factor receptor 2, has demonstrated encouraging anti-cancer activity in gastric cancer within both in vitro and in vivo models. Areas covered: Apatinib's efficacy, tolerability and safety have been evaluated in one Phase II and one Phase III study in metastatic/advanced gastric cancer. In this review, we focus on the mechanism of action of apatinib, its pharmacokinetic profile and its clinical activity in the treatment of advanced/metastatic gastric cancer. Expert commentary: Unfortunately, as yet, there is no definitive biomarker data for apatinib in gastric cancer. |
| Keywords: | Gastric cancer apatinib VEGFR2 angiogenesis chemotherapy |